search button

Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP

  • Authors:
    • Yujin Kobayashi
    • Yoshihiro Hatta
    • Atsuko Hojo
    • Yoshimasa Kura
    • Yoshihito  Uchino
    • Hiromichi Takahashi
    • Satomi Kiso
    • Yukio Hirabayashi
    • Mai Yagi
    • Hitomi  Kodaira
    • Daisuke Kurita
    • Toshitake Tanaka
    • Katsuhiro Miura
    • Noriyoshi Iriyama
    • Sumiko Kobayashi
    • Umihiko Sawada
    • Masahiko Sugitani
    • Jin Takeuchi

  • View Affiliations

  • Published online on: November 22, 2011     https://doi.org/10.3892/etm.2011.387
  • Pages: 304-308
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The addition of rituximab to cyclophosphamide, doxorubicin, vincristine and prednisone [CHOP (i.e., R-CHOP)] is considered to be the standard regimen for treating localized, primary gastric diffuse large B-cell lymphoma (PG-DLBCL). However, few studies have reported the long-term efficacy of R-CHOP therapy in the management of localized PG-DLBCL. In the present study, we performed a retrospective analysis of 11 patients with localized PG-DLBCL, who were treated with R-CHOP at Nihon University Itabashi Hospital and Kasukabe Municipal Hospital (Japan) from 2001 to 2008. Limited stage cancer was defined as stage I/II according to the Lugano staging system for gastrointestinal (GI) lymphomas. The relative dose intensity (RDI) of CHOP therapy was calculated for each patient. The median age of the patients was 68 years (range, 48-82). Gastralgia and anemia were common symptoms at initial presentation. All patients except 1 received 6 cycles of R-CHOP treatment without consolidative radiation therapy or prior surgery. RDI was maintained at over 80% in 9 out of 11 patients. All patients achieved complete remission and the estimated overall survival with a median follow-up of 54 months (range, 39-103) was 100%, without relapse or significant GI adverse effects, such as perforation or bleeding during R-CHOP treatment. No long-term adverse effects of rituximab were recorded during the observation period. Helicobacter pylori infection was diagnosed in 72.7% (8 cases) of the patients, but was eradicated in a limited number of patients. Our data suggest the feasibility and effectiveness of the addition of rituximab to conventional CHOP therapy in the management of localized PG-DLBCL.
View References

Related Articles

Journal Cover

February 2012
Volume 3 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Kobayashi Y, Hatta Y, Hojo A, Kura Y, Uchino Y, Takahashi H, Kiso S, Hirabayashi Y, Yagi M, Kodaira H, Kodaira H, et al: Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP. Exp Ther Med 3: 304-308, 2012
APA
Kobayashi, Y., Hatta, Y., Hojo, A., Kura, Y., Uchino, Y., Takahashi, H. ... Takeuchi, J. (2012). Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP. Experimental and Therapeutic Medicine, 3, 304-308. https://doi.org/10.3892/etm.2011.387
MLA
Kobayashi, Y., Hatta, Y., Hojo, A., Kura, Y., Uchino, Y., Takahashi, H., Kiso, S., Hirabayashi, Y., Yagi, M., Kodaira, H., Kurita, D., Tanaka, T., Miura, K., Iriyama, N., Kobayashi, S., Sawada, U., Sugitani, M., Takeuchi, J."Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP". Experimental and Therapeutic Medicine 3.2 (2012): 304-308.
Chicago
Kobayashi, Y., Hatta, Y., Hojo, A., Kura, Y., Uchino, Y., Takahashi, H., Kiso, S., Hirabayashi, Y., Yagi, M., Kodaira, H., Kurita, D., Tanaka, T., Miura, K., Iriyama, N., Kobayashi, S., Sawada, U., Sugitani, M., Takeuchi, J."Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP". Experimental and Therapeutic Medicine 3, no. 2 (2012): 304-308. https://doi.org/10.3892/etm.2011.387